person · Reporting owner

Foster Jonathan P.

Disclosed activity across 4 companies

Tapewire entity: 26234
SEC CIK: 0001545414

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Autonomix Medical, Inc.AMIX · Entity 8309	Director	January 26, 2024	January 27, 2024
Empery Digital Inc.EMPD · Entity 21	Director	February 18, 2026	February 20, 2026
Moleculin Biotech, Inc.MBRX · Entity 7886	Chief Financial Officer	August 03, 2026	August 05, 2026
Soliton, Inc.SOLY · Entity 132212	Director	December 16, 2021	December 17, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Autonomix Medical, Inc.

Report date January 26, 2024 · Filed January 27, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	725,000	Reported balance Holding disclosure · report date 2024-01-26 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 725,000
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2028-10-06	Direct	Not disclosed	Reported balance Holding disclosure · report date 2024-01-26 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed

Empery Digital Inc.

Report date February 18, 2026 · Filed February 20, 2026

Security / award	Ownership account	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $993,600.00 · Expires 2034-07-12	Direct	Reported balance After 2026-02-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-18 · Other · Disposed 2 · Balance 0 F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2,232,000.00 · Expires 2033-07-26	Direct	Reported balance After 2026-02-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-18 · Other · Disposed 1 · Balance 0 F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,440,000.00 · Expires 2031-05-19	Direct	Reported balance After 2026-02-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-18 · Other · Disposed 1 · Balance 0 F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock.

Moleculin Biotech, Inc.

Report date August 03, 2026 · Filed August 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	305,673	Reported balance After 2026-08-03 transaction · row 1 1 source row Row 1 · 2026-08-03 · Purchase · Acquired 293,333 · Balance 305,673 F1: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Series I WarrantsSEC Table II · derivative / convertible security · Expires 2031-08-03	Direct	1,027,717	Reported balance After 2026-08-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-03 · Purchase · Acquired 879,999 · Balance 1,027,717 F1: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.

Filing footnotes · ownership attribution and instrument terms

F1: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.

Soliton, Inc.

Report date December 16, 2021 · Filed December 17, 2021

Security / award	Ownership account	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-19	Direct	Reported balance After 2021-12-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-12-16 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-06-27	Direct	Reported balance After 2021-12-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-12-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 · Expires 2030-06-19	Direct	Reported balance After 2021-12-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-19	Direct	Reported balance After 2021-12-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.

F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 03, 2026 Filed Aug 5, 2026 20:16 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseSeries I Warrants · Derivative	879,999	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-025929 · rdgdoc.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,027,717 Underlying: Common Stock · 879,999 shares Expires 2031-08-03 F1 · derivative.exercise_price: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. F1 · price: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. Read SEC document
August 03, 2026 Filed Aug 5, 2026 20:16 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	293,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-025929 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,673 F1 · price: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. Read SEC document
June 22, 2026 Filed Jun 25, 2026 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	174	$0.00	$0.00	Disclosure SEC source: 0001437749-26-021610 · rdgdoc.xml · derivative · entry 6 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,718 Underlying: Common Stock · 174 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On June 22, 2023, the reporting person was granted 693 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On June 22, 2023, the reporting person was granted 693 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · balance_after: Includes 100,003 shares of common stock underlying Series E warrants to purchase common stock. Read SEC document
June 22, 2026 Filed Jun 25, 2026 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	41	$3.12	$127.92	Disclosure SEC source: 0001437749-26-021610 · rdgdoc.xml · nonDerivative · entry 4 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,340 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 22, 2026 Filed Jun 25, 2026 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	174	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-021610 · rdgdoc.xml · nonDerivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 20, 2026 Filed Jun 25, 2026 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	109	$0.00	$0.00	Disclosure SEC source: 0001437749-26-021610 · rdgdoc.xml · derivative · entry 5 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,892 Underlying: Common Stock · 109 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 434 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 434 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · balance_after: Includes 100,003 shares of common stock underlying Series E warrants to purchase common stock. Read SEC document
June 20, 2026 Filed Jun 25, 2026 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	31	$2.88	$89.28	Disclosure SEC source: 0001437749-26-021610 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,207 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 20, 2026 Filed Jun 25, 2026 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	109	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-26-021610 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:03 UTC	Empery Digital Inc. EMPD · Entity 21	OtherStock Option (Right to buy) · Derivative	1	$0.00 Strike: $1,440,000.00	$0.00	Disclosure SEC source: 0001683168-26-001214 · ownership.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2031-05-19 F1 · kind: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock. Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:03 UTC	Empery Digital Inc. EMPD · Entity 21	OtherStock Option (Right to buy) · Derivative	1	$0.00 Strike: $2,232,000.00	$0.00	Disclosure SEC source: 0001683168-26-001214 · ownership.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2033-07-26 F1 · kind: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock. Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:03 UTC	Empery Digital Inc. EMPD · Entity 21	OtherStock Option (Right to buy) · Derivative	2	$0.00 Strike: $993,600.00	$0.00	Disclosure SEC source: 0001683168-26-001214 · ownership.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2034-07-12 F1 · kind: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock. Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:08 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantPerformance Based Restricted Stock Units · Derivative	400,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-035184 · rdgdoc.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,017,695 Underlying: Common Stock · 400,000 shares Expires 2035-11-12 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: On November 12, 2025, the Board approved this performance based restricted stock unit. The performance based restricted stock units set forth in this table will vest in 20% installments upon the achievement of certain clinical milestones; provided that upon a change of control (as defined in the 2024 Stock Plan) 100% shall vest. Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:08 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	600,000	Not disclosed Strike: $0.49	Not disclosed	Disclosure SEC source: 0001437749-25-035184 · rdgdoc.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,617,695 Underlying: Common Stock · 600,000 shares Expires 2035-11-12 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 01:24 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	20,625	$0.00	$0.00	Disclosure SEC source: 0001437749-25-033682 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,017,695 Underlying: Common Stock · 20,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On November 4, 2024, the reporting person was granted 82,500 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On November 4, 2024, the reporting person was granted 82,500 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
November 04, 2025 Filed Nov 7, 2025 01:24 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	5,023	$0.50	$2,496.43	Disclosure SEC source: 0001437749-25-033682 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
November 04, 2025 Filed Nov 7, 2025 01:24 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	20,625	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-033682 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
July 21, 2025 Filed Jul 22, 2025 01:47 UTC	Empery Digital Inc. VLCN · Entity 21	GrantCommon Stock	20,000	$10.00	$200,000.00	Disclosure SEC source: 0001683168-25-005261 · ownership.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: The shares of common stock were purchased by the Reporting Person in the Issuer's recently announced private placement with certain accredited and institutional investors, which closed on July 21, 2025. Read SEC document
July 17, 2025 Filed Jul 22, 2025 01:47 UTC	Empery Digital Inc. VLCN · Entity 21	GrantStock options (right to buy) · Derivative	10,000	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001683168-25-005261 · ownership.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-07-17 F2 · price: The stock options were issued by the Issuer in connection with the Reporting Person's service as a director of the Issuer and vest based upon the daily volume weighted average price ("VWAP") of the Issuer's common stock, vesting as to 20% of the underlying shares of common stock upon the VWAP reaching $10 and then in incremental 20% installments until becoming fully vested upon a VWAP of $30. All vesting is subject to the approval by the Issuer's stockholder of a new stock option plan. F2 · derivative.exercise_date: The stock options were issued by the Issuer in connection with the Reporting Person's service as a director of the Issuer and vest based upon the daily volume weighted average price ("VWAP") of the Issuer's common stock, vesting as to 20% of the underlying shares of common stock upon the VWAP reaching $10 and then in incremental 20% installments until becoming fully vested upon a VWAP of $30. All vesting is subject to the approval by the Issuer's stockholder of a new stock option plan. Read SEC document
June 23, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseSeries E Warrants · Derivative	810,810	Not disclosed Strike: $0.37	Not disclosed	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · derivative · entry 8 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,038,320 Underlying: Common Stock · 810,810 shares Expires not disclosed F5 · price: On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. F5 · derivative.exercise_date: On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. F5 · derivative.expiration_date: On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. Read SEC document
June 23, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	270,270	$0.37	$99,999.90	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · nonDerivative · entry 5 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,587 F5 · price: On June 23, 2025, the reporting person acquired 270,270 shares of common stock and Series E warrants to purchase 810,810 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval. Read SEC document
June 22, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	4,328	$0.00	$0.00	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · derivative · entry 7 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,510 Underlying: Common Stock · 4,328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 22, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	1,054	$0.27	$281.42	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · nonDerivative · entry 4 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,317 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 22, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	4,328	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · nonDerivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	2,711	$0.00	$0.00	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · derivative · entry 6 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,838 Underlying: Common Stock · 2,711 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	661	$0.27	$176.49	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,043 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 20, 2025 Filed Jun 23, 2025 20:35 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	2,711	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-021051 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	833	$0.00	$0.00	Disclosure SEC source: 0001437749-25-020803 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,684 Underlying: Common Stock · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 3,334 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 3,334 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	203	$0.69	$139.10	Disclosure SEC source: 0001437749-25-020803 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,993 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 16, 2025 Filed Jun 19, 2025 01:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	833	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-020803 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
November 04, 2024 Filed Nov 7, 2024 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantRestricted Stock Units · Derivative	82,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-24-033704 · rdgdoc.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,337 Underlying: Common Stock · 82,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
November 04, 2024 Filed Nov 7, 2024 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	65,000	Not disclosed Strike: $2.45	Not disclosed	Disclosure SEC source: 0001437749-24-033704 · rdgdoc.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,837 Underlying: Common Stock · 65,000 shares Expires 2034-11-04 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
October 25, 2024 Filed Nov 7, 2024 01:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantPerformance Based Restricted Stock Units · Derivative	19,180	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-24-033704 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,517 Underlying: Common Stock · 19,180 shares Expires 2033-12-29 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F5 · derivative.exercise_date: On December 29, 2023, the Board approved this performance based restricted stock unit, subject to shareholder approval of the stock plan. The performance based restricted stock units set forth in this table will vest only upon both (A) the approval of the Plan Amendment by the Company stockholders; and (B) the first of the following to occur: (a) a licensing transaction with a valuation, at the time, in excess of $150 million, which valuation shall be determined by the Board; (b) the filing of a new drug application; or (c) upon a Change in Control (as defined in the Plan), in each case subject to the respective executive officer's continued service with the Company at each such vesting date. Read SEC document
June 22, 2024 Filed Jun 25, 2024 22:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	4,329	$0.00	$0.00	Disclosure SEC source: 0001437749-24-021198 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,837 Underlying: Common Stock · 4,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 22, 2023, the reporting person was granted 17,313 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 22, 2024 Filed Jun 25, 2024 22:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	1,053	$3.74	$3,938.22	Disclosure SEC source: 0001437749-24-021198 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,363 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 22, 2024 Filed Jun 25, 2024 22:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	4,329	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-24-021198 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	2,712	$0.00	$0.00	Disclosure SEC source: 0001437749-24-020996 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,166 Underlying: Common Stock · 2,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 10,846 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	636	$3.78	$2,404.08	Disclosure SEC source: 0001437749-24-020996 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,087 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 20, 2024 Filed Jun 21, 2024 21:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	2,712	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-24-020996 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	834	$0.00	$0.00	Disclosure SEC source: 0001437749-24-020664 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,878 Underlying: Common Stock · 834 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 3,334 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 3,334 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	196	$4.14	$811.44	Disclosure SEC source: 0001437749-24-020664 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,011 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:01 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	834	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-24-020664 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 26, 2023 Filed Dec 27, 2023 12:32 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	PurchaseCommon Stock	28,986	$0.69	$20,000.34	Disclosure SEC source: 0001437749-23-035342 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,556 Read SEC document
July 12, 2023 Filed Jul 14, 2023 20:03 UTC	Empery Digital Inc. VLCN · Entity 21	GrantStock Option · Derivative	200,000	$0.00 Strike: $0.69	$0.00	Disclosure SEC source: 0001683168-23-004920 · ownership.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,250 Underlying: Common Stock · 200,000 shares Expires 2033-07-12 Read SEC document
June 22, 2023 Filed Jun 26, 2023 22:21 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantRestricted Stock Units · Derivative	259,688	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-018530 · rdgdoc.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,090,626 Underlying: Common Stock · 259,688 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 22, 2023 Filed Jun 26, 2023 22:21 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	GrantStock option (right to buy) · Derivative	150,000	Not disclosed Strike: $0.60	Not disclosed	Disclosure SEC source: 0001437749-23-018530 · rdgdoc.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,938 Underlying: Common Stock · 150,000 shares Expires 2033-06-22 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document
June 20, 2023 Filed Jun 22, 2023 23:02 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	40,667	$0.00	$0.00	Disclosure SEC source: 0001437749-23-018141 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 680,938 Underlying: Common Stock · 40,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 20, 2022, the reporting person was granted 162,667 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 20, 2022, the reporting person was granted 162,667 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 20, 2023 Filed Jun 22, 2023 23:02 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	9,676	$0.57	$5,515.32	Disclosure SEC source: 0001437749-23-018141 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,570 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document
June 20, 2023 Filed Jun 22, 2023 23:02 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionCommon Stock	40,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-23-018141 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
June 16, 2023 Filed Jun 20, 2023 22:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Exercise / conversionRestricted Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0001437749-23-017885 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,605 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 50,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 50,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
June 16, 2023 Filed Jun 20, 2023 22:00 UTC	Moleculin Biotech, Inc. MBRX · Entity 7886	Tax withholdingCommon Stock	3,044	$0.57	$1,735.08	Disclosure SEC source: 0001437749-23-017885 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,579 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.